Business Context and Reporting Period
This Form 8-K Current Report was filed by NanoVibronix, Inc. (Note: Request metadata listed "Envue Medical, Inc.", but the filing text identifies the registrant as NanoVibronix, Inc.) on November 3, 2017, with events reported through November 7, 2017. The company is an emerging growth company incorporated in Delaware, with principal executive offices in Nesher, Israel.
Key Financial Metrics and Capital Structure
The filing does not provide standard operating financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial event reported is a capital raise:
- Offering Proceeds: Approximately $5.1 million (net of underwriting discounts and expenses).
- Shares Issued: 1,224,488 shares of common stock (or equivalents) and warrants to purchase up to 918,366 shares.
- Liquidity Impact: The proceeds were received to support operations, though specific liquidity ratios are not disclosed.
Material Changes and Corporate Actions
The filing details two significant corporate actions:
- Series D Convertible Preferred Stock: On November 3, 2017, the company designated 506 shares of Series D Convertible Preferred Stock.
- Conversion: Convertible into 1,000 shares of common stock at an initial price of $4.90 per share.
- Ownership Limitations: Conversion is restricted if the holder would own more than 4.99% of outstanding common stock (adjustable to 9.99% with notice).
- Liquidation: Holders receive amounts as if converted immediately prior to liquidation, subject to senior securities.
- Dividends: No dividends unless declared by the board; if declared, holders receive amounts equal to common stock dividends on an as-converted basis.
- Voting: No voting rights except as required by law.
- Stock Listing: Following the underwritten offering, the company's common stock began trading on the NASDAQ Capital Market under the ticker symbol "NAOV".
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard terms of the new securities. The primary contingency noted is the beneficial ownership limitation on the conversion of Series D Preferred Stock, which may restrict the ability of holders to convert shares into common stock without prior notice and a waiting period.
Key Facts for Investor Verification
- Verify the ticker symbol "NAOV" on the NASDAQ Capital Market for current trading status.
- Confirm the dilution impact of the 1,224,488 common shares and 918,366 warrant shares issued in the November 7 offering.
- Review the full "Certificate of Designation" (Exhibit 3.1) for detailed adjustment mechanisms regarding the $4.90 conversion price of the Series D Preferred Stock.
- Note that the filing text identifies the company as NanoVibronix, Inc., not Envue Medical, Inc.